triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial is triple-agonist drug targeting GLP-1, GIP, and glucagon receptors to suppress appetite and boost thermogenesis. trials reported 24.2% average weight loss and over 80% liver fat reduction, reversing Retatrutide for Obesity: Phase 2

There was a tsunami wave of these GLP-1 medications last year and whenever I see a medication in high demand, I tend to think about whether theres a non-pharmaceutical alternative with clinical backing, she told NutraIngredients

Kozic, D

Individual responses vary based on hormone levels and the type of treatment used

By replenishing glutathione levels, NAC helps support cellular health and resilience against environmental toxins and other harmful exposures

It helps your body efficiently break down and absorb nutrients, promoting overall well-being

Some studies have explored whether GLP-1 RAs could be used as a standalone treatment or in combination with other therapies for depression